Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom s New CEO to Earn $420K Per Year, Up to $210K in Performance Bonus

NEW YORK, June 3 (GenomeWeb News) - Harry Stylli, Sequenom's newly hired president and CEO, will receive an annual salary of $420,000 and be eligible for an annual performance bonus of up to 50 percent of that salary.

 

When he starts his new job on June 6, Stylli will be eligible to purchase 1 million shares of stock at a price per share equal to the fair market value on his start date, Sequenom said in an SEC filing this week.

 

Stylli will replace Stephen Zaniboni, Sequenom's chief financial officer who has served as acting-CEO since February when Toni Schuh stepped down.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more